Breaking News From Pharma & Bio Ingredients Subscribe via RSS Subscribe via RSS



HIV Vaccine Looks Promising in Phase I


Posted on 2006-12-15 08:02:00



GenVec, Inc. announced today the publication of an article and accompanying editorial reporting positive results of Phase I human trials using this HIV vaccine, in trials being conducted by the National Institutes of Health (NIH) Vaccine Research Center (VRC). It is the first published clinical research on an adenovirus-based HIV vaccine candidate.

In the Phase I dose escalation trial the vaccine was tested in healthy, uninfected adult volunteers, and was found safe and well tolerated at multiple doses. This vaccine is based on GenVec's proprietary adenovirus vector technology. A single injection induced HIV-1 antigen specific T cell responses in 28 (93%) and 18 (60%) of 30 vaccine recipients for CD4 and CD8 T cells, respectively. Env-specific antibody responses were detected in 28 (93%) of 30 vaccine recipients.

The article, Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector, authored by investigators from the NIH Vaccine Research Center, the Fred Hutchinson Cancer Research Center and GenVec, appears in the December 15 issue of the Journal of Infectious Disease (JID2006:194).

In the accompanying editorial, Harriet Robinson, Ph.D., from Emory University and Kent J. Weinhold, Ph.D., from Duke University discuss the strategy being used by the NIH Vaccine Research Center to develop an HIV/AIDS vaccine, which employs a DNA vaccine to prime the immune response and GenVec's rAd5 vaccine technology to boost the response.

"This publication is an important milestone in the HIV vaccine program. We are pleased that the vaccine is well tolerated and immunogenic and has demonstrated an ability to elicit a T-cell response, which is considered to be important in the control of the disease," said C. Richter King, senior vice president of research for GenVec. "We were also pleased at the positive view of the editorial and look forward to additional data from the ongoing VCR Phase II trials, and the planned initiation of a Phase IIb efficacy trial next year."


NEWS ARCHIVES

2008

2007

2006

2005

2004

NEWSLETTER SIGNUP